JPWO2020223514A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223514A5 JPWO2020223514A5 JP2021564834A JP2021564834A JPWO2020223514A5 JP WO2020223514 A5 JPWO2020223514 A5 JP WO2020223514A5 JP 2021564834 A JP2021564834 A JP 2021564834A JP 2021564834 A JP2021564834 A JP 2021564834A JP WO2020223514 A5 JPWO2020223514 A5 JP WO2020223514A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- composition
- sequence
- sgrna
- crrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091079001 CRISPR RNA Proteins 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 101710163270 Nuclease Proteins 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000053602 DNA Human genes 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000030648 nucleus localization Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000000869 mutational effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000768A JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841046P | 2019-04-30 | 2019-04-30 | |
| US62/841,046 | 2019-04-30 | ||
| US201962897806P | 2019-09-09 | 2019-09-09 | |
| US62/897,806 | 2019-09-09 | ||
| US201962931630P | 2019-11-06 | 2019-11-06 | |
| US62/931,630 | 2019-11-06 | ||
| US202062959672P | 2020-01-10 | 2020-01-10 | |
| US62/959,672 | 2020-01-10 | ||
| US202062991285P | 2020-03-18 | 2020-03-18 | |
| US62/991,285 | 2020-03-18 | ||
| PCT/US2020/030782 WO2020223514A2 (en) | 2019-04-30 | 2020-04-30 | Novel omni-50 crispr nuclease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000768A Division JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531347A JP2022531347A (ja) | 2022-07-06 |
| JPWO2020223514A5 true JPWO2020223514A5 (https=) | 2023-05-11 |
| JP2022531347A5 JP2022531347A5 (https=) | 2023-05-11 |
Family
ID=73029467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564834A Pending JP2022531347A (ja) | 2019-04-30 | 2020-04-30 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
| JP2024000768A Pending JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000768A Pending JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11666641B2 (https=) |
| EP (1) | EP3963061A4 (https=) |
| JP (2) | JP2022531347A (https=) |
| KR (2) | KR20250060327A (https=) |
| CN (1) | CN114127274A (https=) |
| AU (2) | AU2020266587B2 (https=) |
| BR (1) | BR112021021912A2 (https=) |
| CA (1) | CA3135759A1 (https=) |
| IL (1) | IL287693A (https=) |
| WO (1) | WO2020223514A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US11946077B2 (en) | 2020-06-04 | 2024-04-02 | Emendobio Inc. | OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleases |
| WO2022098693A1 (en) * | 2020-11-04 | 2022-05-12 | Emendobio Inc. | Novel omni-50 crispr nuclease-rna complexes |
| US20240175013A1 (en) * | 2020-12-14 | 2024-05-30 | Emendobio Inc. | Biallelic knockout of trac |
| WO2022132765A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of b2m |
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| KR20230142740A (ko) | 2021-02-08 | 2023-10-11 | 에멘도바이오 인코포레이티드 | Omni-103 crispr 뉴클레아제 |
| IL307855A (en) * | 2021-04-22 | 2023-12-01 | Emendobio Inc | OMNI CRISPR Nucleases 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226 , 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 news |
| IL310730A (en) * | 2021-08-12 | 2024-04-01 | Emendobio Inc | Engineered high fidelity omni-50 nuclease variants |
| JP2024540558A (ja) * | 2021-11-19 | 2024-10-31 | エメンドバイオ・インコーポレイテッド | 新規なｏｍｎｉ ｃｒｉｓｐｒヌクレアーゼ |
| US20250043260A1 (en) * | 2021-12-01 | 2025-02-06 | Emendobio Inc. | Engineered High Activity Omni-79 Nuclease Variants |
| US20260021141A1 (en) * | 2022-07-15 | 2026-01-22 | Emendobio Inc. | Strategies For Knock-Ins At APLP2 Safe Harbor Sites |
| WO2024042165A2 (en) * | 2022-08-26 | 2024-02-29 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases |
| WO2025043140A1 (en) * | 2023-08-23 | 2025-02-27 | Emendobio Inc. | Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2334794B8 (en) | 2008-09-15 | 2017-04-19 | The Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
| WO2017024047A1 (en) | 2015-08-03 | 2017-02-09 | Emendobio Inc. | Compositions and methods for increasing nuclease induced recombination rate in cells |
| ES2942309T3 (es) | 2015-11-04 | 2023-05-31 | Vertex Pharma | Materiales y métodos para el tratamiento de hemoglobinopatías |
| CN105567735A (zh) * | 2016-01-05 | 2016-05-11 | 华东师范大学 | 一种凝血因子基因突变的定点修复载体系统及方法 |
-
2020
- 2020-04-30 WO PCT/US2020/030782 patent/WO2020223514A2/en not_active Ceased
- 2020-04-30 EP EP20799462.5A patent/EP3963061A4/en active Pending
- 2020-04-30 KR KR1020257013727A patent/KR20250060327A/ko active Pending
- 2020-04-30 BR BR112021021912A patent/BR112021021912A2/pt unknown
- 2020-04-30 JP JP2021564834A patent/JP2022531347A/ja active Pending
- 2020-04-30 KR KR1020217037743A patent/KR102802134B1/ko active Active
- 2020-04-30 US US17/594,761 patent/US11666641B2/en active Active
- 2020-04-30 AU AU2020266587A patent/AU2020266587B2/en active Active
- 2020-04-30 CN CN202080032631.5A patent/CN114127274A/zh active Pending
- 2020-04-30 CA CA3135759A patent/CA3135759A1/en active Pending
-
2021
- 2021-10-28 IL IL287693A patent/IL287693A/en unknown
-
2023
- 2023-04-06 US US18/296,798 patent/US20240226246A9/en active Pending
-
2024
- 2024-01-05 JP JP2024000768A patent/JP2024050582A/ja active Pending
- 2024-04-04 AU AU2024202171A patent/AU2024202171A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102595683B1 (ko) | 변형된 가이드 rna | |
| JPWO2020223514A5 (https=) | ||
| JP2021118726A5 (https=) | ||
| US20190048337A1 (en) | Crispr/Cas-Related Methods and Compositions for Treating Duchenne Muscular Dystrophy and Becker | |
| JP2023093658A5 (https=) | ||
| JP2021530988A5 (https=) | ||
| IL288263B (en) | CRISPR DNA/RNA hybrid polynucleotides and methods of using them | |
| CN105238806A (zh) | 一种用于微生物的CRISPR/Cas9基因编辑载体的构建及其应用 | |
| JP2020507312A5 (https=) | ||
| KR102882704B1 (ko) | CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도 | |
| Khan et al. | CRISPR/dCas9-mediated inhibition of replication of begomoviruses. | |
| EP4041884A1 (en) | A nucleic acid delivery vector comprising a circular single stranded polynucleotide | |
| Latorre et al. | Modified RNAs in CRISPR/Cas9: an old trick works again. | |
| WO2023206872A1 (zh) | 一种工程优化的核酸酶、向导rna、编辑系统和应用 | |
| WO2023098485A1 (zh) | 一种基于c2c9核酸酶的新型基因组编辑系统及其应用 | |
| JPWO2020014577A5 (https=) | ||
| CN105602972B (zh) | 基于CRISPR-Cas9体外改造腺病毒载体的方法 | |
| KR20240157745A (ko) | 변형된 crispr-기반 유전자 편집 시스템 및 사용 방법 | |
| WO2024003810A1 (en) | Guide rna with chemical modifications | |
| EP4405474A1 (en) | High purity grna synthesis process | |
| JP7769691B2 (ja) | 新規の改良された塩基編集または編集用融合タンパク質およびその用途 | |
| KR102679001B1 (ko) | 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도 | |
| US12157886B2 (en) | Type II CRISPR/Cas9 genome editing system and the application thereof | |
| WO2026060637A1 (en) | Engineered mrna for gene editing using crispr/cas12b | |
| JP2002507205A (ja) | 目的の遺伝子を活性化するための組成物および方法 |